Prey J - Search Results

1

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.

Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. Clarke JL, et al. Among authors: prey j. Cancer Chemother Pharmacol. 2017 Mar;79(3):603-610. doi: 10.1007/s00280-017-3247-3. Epub 2017 Feb 23. Cancer Chemother Pharmacol. 2017. PMID: 28233053 Clinical Trial.

2

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.

Ramanathan RK, Korn RL, Raghunand N, Sachdev JC, Newbold RG, Jameson G, Fetterly GJ, Prey J, Klinz SG, Kim J, Cain J, Hendriks BS, Drummond DC, Bayever E, Fitzgerald JB. Ramanathan RK, et al. Among authors: prey j. Clin Cancer Res. 2017 Jul 15;23(14):3638-3648. doi: 10.1158/1078-0432.CCR-16-1990. Epub 2017 Feb 3. Clin Cancer Res. 2017. PMID: 28159813

3

A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.

Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, Creaven PJ, Badmaev V, Prey JD, Rustum YM. Fakih MG, et al. Among authors: prey jd. Cancer Chemother Pharmacol. 2008 Aug;62(3):499-508. doi: 10.1007/s00280-007-0631-4. Epub 2007 Nov 8. Cancer Chemother Pharmacol. 2008. PMID: 17989978 Clinical Trial.

4

A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM. Fakih MG, et al. Among authors: prey jd. Clin Cancer Res. 2006 Feb 15;12(4):1237-44. doi: 10.1158/1078-0432.CCR-05-2004. Clin Cancer Res. 2006. PMID: 16489079 Clinical Trial.

5

Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.

Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF Jr, Prey J, Smith PF, Rustum YM. Azrak RG, et al. Among authors: prey j. Biochem Pharmacol. 2007 May 1;73(9):1280-7. doi: 10.1016/j.bcp.2006.12.020. Epub 2006 Dec 22. Biochem Pharmacol. 2007. PMID: 17239826 Free PMC article.

6

Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis.

Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L. Javle MM, et al. Cancer Invest. 2009 Feb;27(2):193-200. doi: 10.1080/07357900802172093. Cancer Invest. 2009. PMID: 19235592 Clinical Trial.

7

Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase.

Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y, Pendyala L. Hector S, et al. Among authors: prey j. Mol Cancer Ther. 2004 Jul;3(7):813-22. Mol Cancer Ther. 2004. PMID: 15252142

8

Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models.

Lal D, Park JA, Demock K, Marinaro J, Perez AM, Lin MH, Tian L, Mashtare TJ, Murphy M, Prey J, Wetzler M, Fetterly GJ, Wang ES. Lal D, et al. Among authors: prey j. Mol Cancer Ther. 2010 Oct;9(10):2737-51. doi: 10.1158/1535-7163.MCT-10-0334. Epub 2010 Oct 5. Mol Cancer Ther. 2010. PMID: 20924124

9

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R. Adelaiye R, et al. Among authors: prey j. Mol Cancer Ther. 2015 Feb;14(2):513-22. doi: 10.1158/1535-7163.MCT-14-0208. Epub 2014 Dec 17. Mol Cancer Ther. 2015. PMID: 25519701 Free PMC article.

10

Pharmacokinetic measurements of IDN 5390 using electrospray ionization tandem mass spectrometry: structure characterization and quantification in dog plasma.

Song L, Prey JD, Xue J, Kanter P, Manzotti C, Bombardelli E, Morazzoni P, Pendyala L. Song L, et al. Among authors: prey jd. Rapid Commun Mass Spectrom. 2005;19(24):3617-25. doi: 10.1002/rcm.2235. Rapid Commun Mass Spectrom. 2005. PMID: 16299696

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters